Fosfomycin (tromethamine)

Fosfomycin (MK-0955) tromethamine is a blood-brain barrier penetrating, broad-spectrum antibiotic by irreversibly inhibiting an early stage in cell wall synthesis. Fosfomycin tromethamine shows both in vivo and in vitro activity against a wide range of bacteria, including multidrug-resistant (MDR), extensively drug-resistant (XDR), and pan-drug-resistant (PDR) bacteria^[1][2]. In Vitro: Fosfomycin tromethamine is an epoxy antibacterial agent. Compared with other antibacterial agents, it acts by inhibiting the early process of cell wall synthesis^[1].
Fosfomycin tromethamine has bactericidal activity against a variety of gram-negative and gram-positive pathogens, including broad-spectrum production β-Bacteria of lactamase and carbapenemase, and against S. aureus strains with an inhibition rate of 90%^[1].
Fosfomycin tromethamine displays extensive tissue penetration, can be used to research of infections of the CNS, soft tissues, bone, lungs, and abscesses^[2]. In Vivo: Fosfomycin tromethamine (80 mg/kg; i.v.-i.v. or i.v.-p.o.) displays the protective effect on the nephrotoxicity of double beckacin, and is not affected by different administration routes in rats^[3].
Pharmacokinetic of Fosfomycin Tromethamine in Rats^[4]

Dibekacin Dose (mg)	Vdss (l/kg)	β (min-1)	T1/2 (min)	Urinary recovery (%)
30	0.261	0.0244	28.4	85